Featured 13F manager
DAFNA Capital Management LLC Nathan Fischel
Los Angeles, CA 20 processed 13Fs on this site · 2021 Q3–2026 Q2
- $524M
- 88 Positions
- 2026 Q2
- +19.1% QoQ
- Top 5 40.2%
Nathan Fischel files DAFNA Capital Management LLC as a Form 13F. The latest book is 2026 Q2 at $524M, up 19.1% QoQ, led by Revolution Medicines, Spdr S&P Biotech ETF, and Compass Pathways.
Portfolio
top 5 40.2% · top 10 56.2%
- RVMD - Revolution Medicines 20.1%
- XBI - Spdr S&P Biotech ETF 5.9%
- CMPS - Compass Pathways 5.4%
- STXS - Stereotaxis 4.5%
- NKTR - Nektar Therapeutics 4.3%
- DNLI - Denali Therapeutics 3.6%
- IDYA - Ideaya Biosciences 3.5%
- ATRC - Atricure 3.2%
- XENE - Xenon Pharmaceuticals 2.9%
- CYTK - Cytokinetics 2.8%
- RCUS - Arcus Biosciences 2.6%
- ASND - Ascendis Pharma A/S 2.5%
- Other 38.7%
AUM over time
Book
| XBI - Spdr S&P Biotech ETF | 10.36% | Reduce −14.3% | 484,000 | $89.29 | $43M | −81,000 | +$2M |
| CYTK - Cytokinetics | 8.00% | Reduce −16.6% | 400,000 | $83.49 | $33M | −79,538 | +$19M |
| STXS - Stereotaxis | 5.74% | Hold | 13,680,554 | $1.75 | $24M | — | — |
| IDYA - Ideaya Biosciences | 4.40% | Add +3.3% | 516,341 | $35.58 | $18M | +16,521 | +$5M |
| SNDX - Syndax Pharmaceuticals | 3.85% | Add +62.0% | 742,574 | $21.61 | $16M | +284,201 | +$9M |
| ASND - Ascendis Pharma A/S | 3.73% | Reduce −9.4% | 123,472 | $125.95 | $16M | −12,740 | +$3M |
| Karuna Therapeutics | 3.65% | Reduce −8.9% | 48,145 | $316.51 | $15M | −4,728 | +$6M |
| RVMD - Revolution Medicines | 3.52% | Add +8.1% | 511,894 | $28.68 | $15M | +38,500 | +$2M |
| NDAQ - Ishares Nasdaq Biotech Indx | 3.34% | Hold | 102,500 | $135.85 | $14M | — | — |
| XENE - Xenon Pharmaceuticals | 3.05% | Reduce −1.4% | 276,739 | $46.06 | $13M | −3,799 | +$3M |
| Merus | 3.00% | Reduce −6.2% | 454,870 | $27.50 | $13M | −30,000 | +$1M |
| Blueprint Medicines | 2.45% | Reduce −55.6% | 110,863 | $92.24 | $10M | −138,658 | −$2M |
| DAWNGBX — | 2.40% | Add +17.1% | 686,463 | $14.60 | $10M | +100,000 | +$3M |
| NBIX - Neurocrine Biosciences | 2.29% | Reduce −1.4% | 72,615 | $131.76 | $10M | −1,000 | +$1M |
| DXCM - Dexcom | 2.01% | Hold | 67,552 | $124.09 | $8M | — | — |
| Kalvista Pharmaceuticals | 1.76% | Reduce −0.7% | 601,032 | $12.25 | $7M | −4,500 | +$2M |
| BHVN - Biohaven | 1.73% | Add +382.2% | 168,772 | $42.80 | $7M | +133,772 | +$6M |
| KURA - Kura Oncology | 1.70% | Reduce −10.5% | 492,684 | $14.38 | $7M | −58,100 | +$2M |
| Morphic | 1.60% | Hold | 231,748 | $28.88 | $7M | — | — |
| TNDM - Tandem Diabetes Care | 1.56% | Hold | 220,708 | $29.58 | $7M | — | — |
| AXGN - Axogen | 1.53% | Hold | 935,894 | $6.83 | $6M | — | — |
| 2seventy Bio | 1.48% | Hold | 1,447,465 | $4.27 | $6M | — | — |
| Immunogen | 1.38% | Add +133.3% | 193,661 | $29.65 | $6M | +110,661 | +$4M |
| Sage Therapeutics | 1.27% | New | 245,000 | $21.67 | $5M | +245,000 | +$5M |
| LKFT - Galapagos | 1.27% | Add +116.3% | 130,175 | $40.65 | $5M | +70,000 | +$3M |
| Mirati Therapeutics | 1.26% | Reduce −3.8% | 89,387 | $58.75 | $5M | −3,500 | +$1M |
| EWTX - Edgewise Therapeutics | 1.18% | Reduce −13.5% | 449,384 | $10.94 | $5M | −70,000 | +$2M |
| ALEC - Alector | 1.17% | Reduce −3.0% | 609,905 | $7.98 | $5M | −19,033 | +$792K |
| VKTX - Viking Therapeutics | 1.11% | Reduce −22.3% | 248,217 | $18.61 | $5M | −71,438 | +$1M |
| ATRC - Atricure | 1.07% | Hold | 125,529 | $35.69 | $4M | — | — |
| RCUS - Arcus Biosciences | 1.07% | Add +4.5% | 232,717 | $19.10 | $4M | +10,000 | +$447K |
| IPSC - Century Therapeutics | 1.04% | Hold | 1,307,407 | $3.32 | $4M | — | — |
| BCRX - Biocryst Pharmaceuticals | 1.02% | Add +8.8% | 709,500 | $5.99 | $4M | +57,500 | −$366K |
| ARAY - Accuray | 0.83% | Hold | 1,222,358 | $2.83 | $3M | — | — |
| CATBUSD - Astria Therapeutics | 0.83% | Add +52.0% | 449,008 | $7.68 | $3M | +153,515 | +$1M |
| Keros Therapeutics | 0.71% | Add +12.7% | 74,361 | $39.76 | $3M | +8,400 | +$854K |
| Acelyrin | 0.66% | Add +4984.9% | 371,200 | $7.46 | $3M | +363,900 | +$3M |
| PRCT - Procept Biorobotics | 0.64% | Reduce −5.9% | 63,300 | $41.91 | $3M | −4,000 | +$445K |
| Mediwound | 0.63% | Hold | 257,653 | $10.17 | $3M | — | — |
| BCYC - Bicycle Therapeutics | 0.53% | Hold | 122,200 | $18.08 | $2M | — | — |
| BWAY - Brainsway | 0.48% | Reduce −28.6% | 308,471 | $6.48 | $2M | −123,710 | +$253K |
| PRQR - Proqr Therapeutics | 0.45% | Hold | 940,582 | $1.98 | $2M | — | — |
| AMLX - Amylyx Pharmaceuticals | 0.43% | Hold | 122,547 | $14.72 | $2M | — | — |
| Mereo Biopharma Group | 0.43% | Reduce −19.1% | 778,813 | $2.31 | $2M | −183,700 | +$557K |
| IMVT - Immunovant | 0.41% | Add +81.1% | 40,742 | $42.13 | $2M | +18,242 | +$853K |
| SPRY - Ars Pharmaceuticals | 0.41% | New | 311,169 | $5.48 | $2M | +311,169 | +$2M |
| CMPS - Compass Pathways | 0.40% | Hold | 193,000 | $8.75 | $2M | — | — |
| Syros Pharmaceuticals | 0.40% | Reduce −19.2% | 214,885 | $7.79 | $2M | −50,993 | +$624K |
| Spruce Biosciences | 0.39% | Reduce −3.8% | 548,510 | $2.93 | $2M | −21,620 | +$319K |
| LRMR - Larimar Therapeutics | 0.35% | Reduce −1.1% | 323,873 | $4.55 | $1M | −3,500 | +$180K |
| Macrogenics | 0.35% | Reduce −41.1% | 152,250 | $9.62 | $1M | −106,246 | +$260K |
| Regulus Therapeutics | 0.34% | Hold | 1,111,049 | $1.28 | $1M | — | — |
| ARGX - Argen Se | 0.33% | New | 3,600 | $380.43 | $1M | +3,600 | +$1M |
| Gossamer Bio | 0.32% | Hold | 1,476,052 | $0.9125 | $1M | — | — |
| CGEM - Cullinan Oncology | 0.31% | Hold | 127,284 | $10.19 | $1M | — | — |
| AUTL - Autolus Therapeutics | 0.29% | Reduce −79.4% | 191,070 | $6.44 | $1M | −737,183 | −$932K |
| Sutro Biopharma | 0.29% | Hold | 283,079 | $4.29 | $1M | — | — |
| Immatics | 0.26% | New | 105,000 | $10.53 | $1M | +105,000 | +$1M |
| Iteos Therapeutics | 0.26% | Hold | 98,560 | $10.95 | $1M | — | — |
| Neuronetics | 0.22% | Hold | 313,717 | $2.90 | $910K | — | — |
| ORIC - Oric Pharmaceuticals | 0.16% | New | 72,797 | $9.20 | $670K | +72,797 | +$670K |
| ACRV - Acrivon Therapeutics | 0.15% | Add +70.9% | 131,351 | $4.92 | $646K | +54,499 | −$88K |
| Nevro | 0.14% | Hold | 28,000 | $21.52 | $603K | — | — |
| Compugen | 0.10% | Hold | 205,202 | $1.98 | $406K | — | — |
| Masimo | 0.08% | Hold | 3,000 | $117.21 | $352K | — | — |
| Adaptimmune Therapeutics | 0.07% | Hold | 351,064 | $0.7930 | $278K | — | — |
| Vigil Neuroscience | 0.06% | Reduce −58.3% | 71,815 | $3.38 | $243K | −100,493 | −$686K |
| Elevation Oncology | 0.06% | Hold | 450,000 | $0.5370 | $242K | — | — |
| Vistagen Therapeutics | 0.05% | New | 41,886 | $5.14 | $215K | +41,886 | +$215K |
| Spero Therapeutics | 0.04% | Hold | 125,000 | $1.47 | $184K | — | — |
| CMPX - Compass Therapeutics | 0.04% | Hold | 116,882 | $1.56 | $182K | — | — |
| Karyopharm Therapeutics | 0.04% | Hold | 192,678 | $0.8650 | $167K | — | — |
| MLYS - Mineralys Therapeutics | 0.03% | New | 15,200 | $8.60 | $131K | +15,200 | +$131K |
| Kinnate Biopharma | 0.03% | Reduce −52.5% | 50,000 | $2.37 | $119K | −55,179 | −$29K |
| INGN - Inogen | 0.02% | Hold | 15,000 | $5.49 | $82K | — | — |
Showing top 50 of 75 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2023 Q3
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| NRIX - Nurix Therapeutics | 1.36% | Exit | 0 | $7.86 | $4M | −556,695 | −$4M |
| Third Harmonic Bio | 0.60% | Exit | 0 | $6.39 | $2M | −300,000 | −$2M |
| Cerevel Therapeutics | 0.42% | Exit | 0 | $21.83 | $1M | −62,200 | −$1M |
| Adicet Bio | 0.34% | Exit | 0 | $1.37 | $1M | −797,054 | −$1M |
| Mersana Therapeutics | 0.29% | Exit | 0 | $1.27 | $932K | −734,038 | −$932K |
| Nextcure | 0.07% | Exit | 0 | $1.29 | $214K | −166,185 | −$214K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 88 | $524M | +19.1% | 13F-HR | 8/14/2026 | 000138993326000006 |
| 2026 Q1 | 83 | $440M | +2.1% | 13F-HR | 5/15/2026 | 000138993326000004 |
| 2025 Q4 | 77 | $431M | +6.4% | 13F-HR | 2/17/2026 | 000138993326000002 |
| 2025 Q3 | 75 | $405M | +11.9% | 13F-HR | 11/14/2025 | 000138993325000008 |
| 2025 Q2 | 76 | $362M | +2.5% | 13F-HR | 8/14/2025 | 000138993225000011 |
| 2025 Q1 | 83 | $353M | −10.2% | 13F-HR | 5/15/2025 | 000138993325000002 |
| 2024 Q4 | 82 | $393M | −7.1% | 13F-HR | 2/14/2025 | 000138993225000004 |
| 2024 Q3 | 84 | $423M | +1.0% | 13F-HR | 11/14/2024 | 000138993224000020 |
| 2024 Q2 | 83 | $419M | −4.6% | 13F-HR | 8/14/2024 | 000138993224000016 |
| 2024 Q1 | 72 | $439M | +5.3% | 13F-HR | 5/15/2024 | 000138993224000012 |
| 2023 Q4 | 76 | $417M | +29.9% | 13F-HR | 2/14/2024 | 000138993224000004 |
| 2023 Q3 | 75 | $321M | −12.3% | 13F-HR | 11/14/2023 | 000138993223000010 |
| 2023 Q2 | 73 | $366M | +9.6% | 13F-HR | 8/14/2023 | 000138993323000008 |
| 2023 Q1 | 72 | $334M | −5.9% | 13F-HR | 5/15/2023 | 000138993323000006 |
| 2022 Q4 | 79 | $355M | −4.6% | 13F-HR | 2/14/2023 | 000138993323000002 |
| 2022 Q3 | 87 | $372M | +1.4% | 13F-HR | 11/14/2022 | 000138993322000010 |
| 2022 Q2 | 90 | $367M | −4.4% | 13F-HR | 8/15/2022 | 000138993322000008 |
| 2022 Q1 | 94 | $384M | −3.5% | 13F-HR | 5/16/2022 | 000138993322000006 |
| 2021 Q4 | 87 | $398M | +5.6% | 13F-HR | 2/14/2022 | 000138993322000002 |
| 2021 Q3 | 80 | $377M | — | 13F-HR | 11/15/2021 | 000138993321000011 |
About
DAFNA Capital Management LLC
20 processed 13Fs on this site · 2021 Q3–2026 Q2